One strategy that has shown over time to be effective in beating the market is tracking insider buying since insiders are just like the rest of the public in how they desire to make more money and as a result when these people purchase shares who arguably have the best view into a company's operations and future prospects, we can join them on the way higher. The following are stocks that have recently had notable insider buying of at least $200,000 and seemed poised to move higher as the fundamentals and/or future prospects look compelling. As a caveat, please only consider this as a starting point in your investment research as these are only the opinions of the blogger:
One of the world's fast food restaurants YUM! Brands (NYSE:YUM) operates over 38,000 restaurants collectively with well-known restaurants such as Taco Bell, KFC, and Pizza Hut under their umbrella. With an annual revenue base over $13.5 billion and market capitalization near $30 billion, the company is a behemoth. Unfortunately though, the company recently had a disappointing quarter that sent the stock plunging and had investors thinking twice about its future prospects. Board director Robert Walter seems to think its a buying opportunity scooping up 35,000 shares on February 6 equating to over $2.1 million worth of stock. Looking at the fundamentals with the company churning returns on equity in excess of 76%, returns on assets of 16%, and stellar free cash flow in excess of $1 billion annually, I think YUM is worth buying as well. Moreover, with a 2.1% dividend yield that is consistently growing, investors get paid a nice rate while they wait.
Tyson Foods (NYSE:TSN) is one of the largest meat products companies in the world with over $33 billion in annual sales and a market capitalization nearing $8.5 billion. The company's stock has been on an absolute tear sitting right near its $23.90 52-week high. Some people would understandably feel that the stock is getting too richly priced, but board director Jim Kever thinks otherwise buying a sizeable 10,000 shares on the open market on February 6 at $23.369 or almost $250,000 worth of stock. The company has done well operationally greatly exceeding analyst estimates in three of the last four quarters while still expected to show some nice growth of 8.5% per annum going forward. The company also still trades as some decent valuations of 10x forward P/E, just .3x enterprise value to sales, and only 5.5x enterprise value to EBITDA. Add in the fact that as the size of the middle class continues to grow worldwide (predominately BRIC countries) and I think Tyson has the makings of a stock continuing to go higher.
DaVita Healthcare Partners (NYSE:DVA) is focused on specialized health services predominately relating to kidney dialysis treatment. The company has also done extremely well up approximately 50% year over year and sitting also right at its $119.09 52-week high. Nonetheless, major shareholder and value legend Berkshire Hathaway see the stocks moving higher buying 32,376 shares on February 5 equating to over $3.7 million worth of stock. The company has met or exceeded analyst estimates the last four quarters and analysts are expecting nice growth in excess of 13% per annum over the next five years. With a 22% return on equity, relatively cheap 16x forward P/E, and now having Berkshire Hathaway as its largest holder, I think DaVita is a buy.
CarMax (NYSE:KMX) is one of the largest auto dealership in the nation with 117 in 58 different markets as of December 20, 2012. This stock is also just barely below its $40.22 52-week high as the stock is benefiting from a rebounding economy and consumer confidence. Nevertheless, board director Rakesh Gangwal bought 30,000 shares on February 7 equating to almost $1.2 million worth of stock. The company though has missed analyst estimates though in two of the last three quarters while valuations look comparatively pricey. CarMax is trading at over .8x price/sales and 19x forward Price/Earnings while its fellow competitor AutoNation is trading at a much more attractive .4x price/sales and 15x forward Price/Earnings and expected to grow at a similar 11-12% per annum over the next five years. CarMax does have higher margins, but it looks as though its more than priced into the stock so I would hold off for now.
Opko Health (NYSE:OPK) is a biopharmaceutical company based out of Miami while having operations in Mexico and Chile as well. This is yet another company that has scorched higher lately and not sitting far off its $7.22 52-week high. Chairman, CEO, and major shareholder Dr. Frost sees continued great times ahead buying on February 37,500 shares equating to over $250,000 worth of stock. As most biotechnology stocks, the company's fundamentals are ugly as they wait to hit the next blockbuster drug. Nevertheless, the company has met or exceeded analyst estimates in three of the last four quarters and has a promising pipeline. Add in the fact that the Chairman and CEO is buying so heavily and this may be worth a look for the more speculative investor.
Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in DVA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.